Loading...
Market
How many participants will be enrolled in post-approval studies of Sunlenca by end of 2024?
2
Resolution / Starting Odds
0-1000 • 25%
1001-2000 • 25%
2001-3000 • 25%
3001+ • 25%
Clinical trial registries and reports
Story
Gilead's Sunlenca Shows 100% Efficacy in HIV Prevention Trial
Jun 20, 2024, 12:54 PM
Gilead Sciences announced that its twice-yearly injectable antiviral drug, lenacapavir, also known as Sunlenca, demonstrated 100% efficacy in preventing HIV infection in women during a late-stage trial. The study, which included over 2,000 women, showed that lenacapavir was more effective than the company's existing daily pill, Truvada. Researcher Joe Eron described the results as remarkable, noting that there were no infections among the participants. This trial is part of Gilead's most comprehensive and diverse HIV prevention program to date, underscoring the company's commitment to serving the needs of individuals seeking pre-exposure prophylaxis (PrEP).
View original story
Similar markets
More than 20 countries • 33%
10 to 20 countries • 34%
Less than 10 countries • 33%
0 • 25%
1 • 25%
2 • 25%
3 or more • 25%
0 new indications • 33%
1 new indication • 33%
2 or more new indications • 34%
0-10 • 25%
11-30 • 25%
31-60 • 25%
61+ • 25%
Less than 5,000 • 25%
5,000 to 10,000 • 25%
10,001 to 20,000 • 25%
More than 20,000 • 25%
Less than 100 • 25%
100 - 500 • 25%
500 - 1000 • 25%
More than 1000 • 25%
0-10 • 25%
11-30 • 25%
31-60 • 25%
61-120 • 25%
Less than 50 • 25%
50 to 100 • 25%
101 to 200 • 25%
More than 200 • 25%
None • 33%
1-3 • 33%
More than 3 • 33%
0 • 25%
1 - 2 • 25%
3 - 4 • 25%
5 or more • 25%
Less than 10 • 25%
10 to 20 • 25%
21 to 30 • 25%
More than 30 • 25%